Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Cavion General Information
Cavion’s lead clinical program, CX‑8998, has been evaluated in the T-CALM trial for essential tremor. The company focuses on modulating the Cav3 channel to address movement disorders and rare epilepsies. As of its acquisition by Jazz Pharmaceuticals in August 2019, it was a clinical-stage company with ongoing trials[1][2].
Contact Information
Primary Industry
Biotech
Corporate Office
Charlottesville, Virginia
United States
United States
Drug Pipeline
CX-8998
Phase 2Key Partnerships
Cavion Funding
No funding data available
To view Cavion's complete valuation and funding history, request access »